P.I. Works Celebrates 20 Years of Shaping the Telecom Industry
P.I. Works, the leading independent provider of AI-driven mobile network automation, optimization, and assurance solutions, proudly celebrates its 20th anniversary. This milestone marks two decades of driving telecom innovation and enabling mobile operators to deliver superior network performance, operational efficiency, and customer experience worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021105217/en/
P.I. Works Celebrates 20 Year Anniversary
From Network Optimization to AI-Driven Automation
Founded in 2005, as mobile data traffic surged with the rise of 3G, P.I. Works introduced intelligent solutions to help operators plan, manage, and optimize their networks more efficiently. Over the years, the company pioneered Self-Organizing Network (SON) capabilities, establishing the foundation for large-scale automation and giving operators the agility to manage increasingly complex networks.
Leading Through the 5G Era and Beyond
As the telecom industry transitioned into the 5G era, P.I. Works expanded its portfolio to include real-time optimization, predictive analytics, energy-efficient automation, and advanced RAN slicing assurance. These AI-driven solutions help operators manage soaring data demand, diversify service offerings, and meet evolving customer expectations.
With a massive global footprint including deployments at 85 operators across 58 countries, serving over 1.7 billion subscribers, P.I. Works continues to redefine how operators run their networks by offering vendor-agnostic solutions that empower them with independence, flexibility, and resilience, enabling lasting impact in a rapidly changing technology environment.
A Commitment to Innovation and Sustainability
“Celebrating 20 years of innovation is both a milestone and a commitment,” said Başar Akpınar, CEO & Co-founder of P.I. Works. “We remain committed to empowering operators with openness and vendor independence helping them design and operate truly autonomous networks that are intelligent and agile.”
P.I. Works’ 20th anniversary marks a renewed commitment to innovation, sustainability, and operator independence as mobile networks evolve toward greater autonomy in the 5G era and beyond.
About P.I. Works
P.I. Works is a global leader in AI-driven mobile network automation, optimization, and assurance. For two decades, we have partnered with mobile operators worldwide to transform networks, reduce costs, improve energy efficiency, strengthen independence, and deliver superior customer experiences. Together with our customers, we shape the future of network excellence.
www.piworks.net
View source version on businesswire.com: https://www.businesswire.com/news/home/20251021105217/en/
Contacts
For further information, please contact excellence@piworks.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF and BASF Announce Strategic Collaboration to Drive Next-Generation Enzyme and Polymer Innovation21.10.2025 13:00:00 EEST | Press release
IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences — announced a strategic collaboration with BASF, one of the world’s largest chemical companies and leader in sustainable product innovation, to accelerate the development of IFF’s Designed Enzymatic Biomaterials™ technology platform and create next-generation enzyme technologies for fabric, dish and personal care as well as industrial cleaning applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021911702/en/ Photo credit: IFF This collaboration brings together two industry leaders with a shared vision: to develop high-performance, sustainable solutions that meet evolving consumer and market demands. By combining advanced chemical capabilities and expertise in biotechnology and protein engineering from IFF and BASF, the partnership aims to deliver breakthrough solutions at scale that enhance cleaning performance, imp
Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule21.10.2025 12:12:00 EEST | Press release
Spanish international pharmaceutical company Ferrer has announced the completion of patient recruitment for the PROSPER study, a Phase II clinical trial designed to assess the efficacy, safety, and pharmacokinetics of FNP-223, an orally available, potent and selective inhibitor of the OGA enzyme, in-licensed from Asceneuron, aimed at slowing disease progression in Progressive Supranuclear Palsy (PSP)1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021806533/en/ Ferrer's pharmaceutical production plant in Sant Cugat del Valles, Barcelona, Spain. PSP is a rare, rapidly progressive and ultimately fatal neurodegenerative disease2. To date, no disease-modifying therapies have been approved for PSP. The PROSPER study is a randomized, double-blind, placebo-controlled trial3 that has successfully recruited the planned number of 220 participants with PSP in just 14 months, achieving this milestone on October 6th, two months ahead
Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar21.10.2025 11:51:00 EEST | Press release
Polpharma Biologics today announced Ranivisio® PFS (ranibizumab biosimilar pre-filled syringe), is now commercially available in France. Ranivisio® is the first Lucentis® biosimilar which is offered in a convenient pre-filled syringe (PFS) presentation in Europe, setting a new standard for affordable biologics in ophthalmic care. This innovative configuration provides precise dosing and ease of use, supporting efficient administration for patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Bioeq AG, a joint venture between Polpharma Biologics Group BV and Formycon AG, is responsible for the development and licensing of Ranivisio® PFS. Teva holds the commercialization rights for France under an exclusive licensing agreement with Bioeq. The drug substance for Ranivisio® PFS is manufactured by Polpharma Biologics S.A. - a contract development and manufacturing organization (CDMO) operating under the Rezon
NTT DATA Strengthens Global Insurance Leadership with Acquisition of Alchemy Technology Services21.10.2025 11:00:00 EEST | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced the acquisition of Alchemy Technology Services, a specialist insurance technology consultancy. The move reinforces NTT DATA’s commitment to transforming the global insurance ecosystem, addressing current and emerging challenges around agility, modernization and scalability. In addition to its strong consultancy and Guidewire credentials, Alchemy brings deep expertise in the specialty insurance market, particularly in supporting complex and regulated environments, such as the London Market, the largest (re)insurance subscription market globally. This will further strengthen NTT DATA’s ability to serve niche and high-value segments across the global insurance landscape. A shared vision for insurance innovation This acquisition marks a significant milestone in NTT DATA’s strategy to lead the digital reinvention of the insurance sector - a market set to reach $230.7 billion in IT spend this year. Bui
Impartner Expands European Infrastructure to Accelerate Growth and Customer Support Across EMEA21.10.2025 11:00:00 EEST | Press release
Impartner, the leading provider of Partner Relationship Management (PRM) solutions, today announced the expansion of its European infrastructure with a new Azure-based data centre in the Netherlands. This milestone reflects Impartner’s accelerating success across the EMEA region and its commitment to providing customers with the highest levels of security, compliance, performance and support. “Our EMEA business continues to grow rapidly as companies across the region look to Impartner to scale their partner ecosystems,” said Curtis Brinkerhoff, CRO of Impartner. “Expanding our infrastructure within Europe, in close collaboration with Microsoft, ensures we are not only meeting strict EU data residency and privacy standards, but also strengthening performance and responsiveness for our customers across all industries.” By hosting in Microsoft’s Netherlands Azure data centre, Impartner customers benefit from the assurance of GDPR-compliant data handling, best-in-class security and the spe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom